References
- Thames HD, Hendry JH. In hindsight. In: Fractionation in Radiotherapy. Thames HD, Hendry JH (Eds). Taylor & Francis, London, UK 137–148 (1987).
- Coutard H. Roentgentherapy of epitheliomas of the tonsillar region, hypopharynx, and larynx from 1920 to 1926. Am. J. Roentgenol.28, 313–331 (1932).
- Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer? Int. J. Radiat. Oncol. Biol. Phys.56(4), 1093–1104 (2003).
- Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol.44(3), 265–276 (2005).
- Miles EF, Lee WR. Hypofractionation for prostate cancer: a critical review. Semin. Radiat. Oncol.18(1), 41–47 (2008).
- Morton GC. The emerging role of high-dose-rate brachytherapy for prostate cancer. Clin. Oncol. (R. Coll. Radiol.)17(4), 219–227 (2005).
- Yoshioka Y, Nose T, Yoshida K et al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a Phase I/II clinical trial. Int. J. Radiat. Oncol. Biol. Phys.48(3), 675–681 (2000).
- Yoshioka Y, Konishi K, Oh RJ et al. High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother. Oncol.80(1), 62–68 (2006).
- Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int. J. Radiat. Oncol. Biol. Phys.37(5), 1035–1041 (1997).
- Martinez AA, Pataki I, Edmundson G, Sebastian E, Brabbins D, Gustafson G. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int. J. Radiat. Oncol. Biol. Phys.49(1), 61–69 (2001).
- Grills IS, Martinez AA, Hollander M et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J. Urol.171(3), 1098–1104 (2004).
- Martinez A, Demanes DJ, Ghilezan M, Schour L, Mitchell C, Gustafson G. 5-year results using HDR monotherapy for patients with favorable prostate cancer. Brachytherapy7, 92 (2008).
- Roach M 3rd, Hanks G, Thames H Jr et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG–ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys.65(4), 965–974 (2006).
- Martin T, Baltas D, Kurek R et al. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther. Onkol.180(4), 225–232 (2004).
- Corner C, Rojas AM, Bryant L, Ostler P, Hoskin P. A Phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.72(2), 441–446 (2008).
- Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int. J. Radiat. Oncol. Biol. Phys.67(4), 1099–1105 (2007).
- King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective Phase II clinical trial. Int. J. Radiat. Oncol. Biol. Phys. DOI 10.1016/j.ijrobp.2008.05.059 (2008).